Pershing Square Reports Q1 & April Financials, AUM Jumps Post-PSUS IPO
Summary
Pershing Square Inc. disclosed Q1 and April 2026 financial results, showing a significant increase in Assets Under Management driven by the successful PSUS IPO, despite a Q1 net loss.
Key Events
-
AUM Growth Post-IPO
Total Assets Under Management (AUM) increased by $6.4 billion from March 31, 2026, to April 30, 2026, reaching $33.0 billion, primarily driven by the $4.9 billion raised from the Pershing Square USA, Ltd. (PSUS) IPO.
-
Fee-Paying AUM Increase
Fee-Paying AUM (FPAUM) also saw a substantial rise, growing by $6.3 billion to $23.3 billion by April 30, 2026, reflecting the new capital from PSUS.
-
Mixed Q1 Financials
Fee-Related Earnings (FRE) increased to $47.7 million in Q1 2026 from $42.4 million in Q1 2025. However, Distributable Earnings (DE) slightly decreased, and the company reported a net loss of $147.6 million for Q1 2026, largely due to unrealized losses on HHH shares.
-
Enhanced Transparency
The company provided additional April 2026 financial data to offer a clearer view of performance following the combined IPO and NYSE listing, which closed on April 30, 2026.
Analysis
Pershing Square Inc. has released its financial supplement for Q1 and April 2026, revealing a significant increase in Assets Under Management (AUM) and Fee-Paying AUM (FPAUM) following the successful initial public offering of Pershing Square USA, Ltd. (PSUS) which closed on April 30, 2026. While Fee-Related Earnings (FRE) saw an increase, Distributable Earnings (DE) slightly decreased, and the company reported a net loss for Q1 2026, largely due to unrealized losses on Howard Hughes Holdings Inc. (HHH) shares. The substantial growth in AUM from the PSUS IPO is a key highlight, demonstrating successful capital raising and expanding the firm's fee-generating asset base.
At the time of this filing, PS was trading at $38.36 on NYSE in the Finance sector. The 52-week trading range was $22.01 to $54.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.